MEM-288 Oncolytic Virus Trial
Phase 1
40
about 9.7 years
18+
2 sites in FL, NC
About this study
This trial is testing a new treatment, MEM-288, which is an oncolytic virus. It's being tested alone and in combination with standard cancer treatments like docetaxel and nivolumab to see if it can help people with advanced solid tumors.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive MEM-288 Intratumoral Injection
- 2.Receive Nivolumab
- 3.Take Docetaxel
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
docetaxel, nivolumab (Immune checkpoint inhibitor; blocks PD-1 receptor on T cells)
infusion, injection
Primary: Part 1A Monotherapy: Maximum Tolerated Dose (MTD), Safety and Tolerability assessed by Adverse Events (AEs)
Secondary: Disease Control Rate (DCR), Overall Response Rate (ORR), Overall Survival (OS), Progression Free Survival (PFS)
Oncology